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Although radiotherapy (RT) is one of the major cancer 
treatment modalities to kill malignant cells, advanced-stage 
disease is often hard to control. Radiation-induced tumor cell 
death provides a plethora of pro-immunogenic effectors 
associated with inflammation. Although the potential for RT 
to generate anti-tumor immunity is apparent, the evidence 
that it does so in the clinical situation is limited. Stimulation 
of the immune system to assist in eliminating cancer cells 
within, and outside, the radiation field could be beneficial in 
advanced-stage or metastasized disease. Recently, it has 
been demonstrated that cancer patients have increased 
levels of cytotoxic T-cells after radiotherapy, making them 
eligible for immunotherapy. Interleukin-2 (IL2) is one of the 
essential cytokines for driving proliferation and 
differentiation of T-cells and NK-cells resulting in increased 
cytotoxic activity, eventually leading to tumor regression. 
Several studies have shown synergistic anti-tumor effects 
when combining RT with systemic IL2 administration, 
although this strategy was accompanied with severe adverse 
effects. 
Monoclonal antibodies, such as the human recombinant scFv 
fragment L19, have been designed as “targeting vehicle” for 
the selective delivery of immune-stimulatory cytokines to the 
tumor microenvironment while sparing normal tissue. The 
L19 antibody selectively localizes at the tumor neovascular 
fibronectin extra-domain B (EDB) positive sites following 
systemic administration and can serve as delivery vehicle for 
IL2. Our lab has combined single high-dose RT with systemic 
L19-IL2 administration in a number of murine xenograft 
models and found outstanding, long-lasting complete 
response rates mediated by cytotoxic CD8+ T-cell (1,2) or NK-
cell (3) activity depending on the tumor model. L19-IL2 is 
thus an immunocytokine with strong immune response 
enhancing properties in EDB-positive tumors. 
The combination therapy resulted also in anti-tumor immune 
effects outside the radiation field, an effect associated with 
CD4+ T-cell response. Growth of secondary un-irradiated 
tumors was significantly delayed with even 20% cure. Similar 
results were found when irradiation was delivered in a 
fractionated manner, although without resulting in cures. An 
increased PD-1 expression on T-cells infiltrating these tumors 
suggests a more regulatory immunological phenotype after 
fractionated radiotherapy compared with a single high RT 
dose. Re-challenging cured animals with tumor cells did not 
result in tumor formation, associated with high CD127 
expression. Our recent data show that radiotherapy 
combined with the immunocytokine L19-IL2 results in long-
lasting complete response rates, also outside the radiation 
field (abscopal effect) and this effect is associated with a 
memory potential. 
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Purpose: Tin-117m is a radionuclide of interest for cancer 
and cardiovascular disease therapies. It has a half-life of 13.6 
days and emits conversion and Auger electrons. It is actually 
used in clinical trials, where the radiopharmaceutical is 
developed by Clear Vascular Inc., to treat vulnerable plaque 
[1]. For this application, tin-117m is produced by the 
irradiation of Cd-116 enriched target with alpha particles. 
The goal of this study is to determine the irradiation 
conditions to get the highest specific activity of the final 
product, based on this reaction. 
Materials/methods: Tin-117m production study has been 
investigated at the ARRONAX [2] cyclotron (France) that is 
able to deliver alpha particles at 67.4 MeV. Production cross 
section measurements of tin-117m as well as radioactive 
contaminants have been made using the stacked-foils 
technique. It consists in the irradiation of a group of thin 
foils: target, monitor and degrader. The stacks were made of 
thin natural cadmium as targets and aluminum foils as 
degraders. Monitor foils acted also as catcher and were made 
of different material depending on the energy. After 
irradiation, the activity of each radionuclides produced in the 
foils has been determined by γ spectrometry [3]. Production 
of stable and long live isotopes has been estimated with the 
TALYS code [4]. From the cross section data, thick target 
production yields (TTY) have been calculated as well as tin-
117m specific activity (SA). 
Results: The production cross section values obtained for the 
Cd-116(α,x) reaction up to 65 MeV have been compared with 
the literature. From these data, Sn-117m TTY has been 
calculated considering a 100% Cd-116 enriched target. A TTY 
of 6.3 MBq/(µA.h) is obtained for 65 MeV alpha particles on a 
thick target. Our results are compared with the value 
reported by Clear Vascular Inc. at 47 MeV. A difference of 
only 6.3 % has been found. In order to determine the SA, the 
mass of stable and long live tin isotopes produced during the 
irradiation have been determined using the TALYS code. The 
figure 1 shows the tin-117m SA in kCi/g from 25 to 65 MeV. 
The maximum tin-117m SA is reached around 40 MeV with 41 
kCi/g and corresponds to a TTY of around 4 MBq/(µA.h). 
Clear Vascular Inc. reported a value of 25 kCi/g at 47 MeV. 
This value is 28 % lower than what is expected from our 
calculation.  
 
